Articles published by Genentech




FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
February 12, 2025
From Genentech
Via Business Wire
Tickers
RHHBY








Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
November 26, 2024
From Genentech
Via Business Wire
Tickers
RHHBY

Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
November 05, 2024
From Genentech
Via Business Wire
Tickers
RHHBY





Positive Phase III Results for Genentech’s Gazyva Show Superiority to Standard Therapy Alone in People With Lupus Nephritis
September 26, 2024
From Genentech
Via Business Wire
Tickers
RHHBY

Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses
September 19, 2024
From Genentech
Via Business Wire
Tickers
RHHBY


FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
September 12, 2024
From Genentech
Via Business Wire
Tickers
RHHBY

New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions
July 18, 2024
From Genentech
Via Business Wire
Tickers
RHHBY



Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
July 08, 2024
From Genentech
Via Business Wire
Tickers
RHHBY

FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
July 05, 2024
From Genentech
Via Business Wire
Tickers
RHHBY



Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.